Can we interrogate public databases to fill critical gaps in mental health epidemiology? Testing the association between cannabis and psychosis in the UK as an example
Gianfranco Di Gennaro, Marco Colizzi
Epidemiology and Psychiatric Sciences 2023 DOI: 10.1017/s2045796023000537 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Cannabis |
| Key points | Argues that prospective studies since 1987 support a causal, dose-response link between cannabis use and psychosis, with high-potency varieties conferring the greatest risk. Using Google Trends and "Our World in Data", the authors report that UK interest in cannabis grew for over 10 years alongside a parallel rise in psychosis cases and prevalence, and propose that such public databases offer public health opportunities. |
Abstract
Abstract The psychoactive properties of cannabis have been known forever. Since 1987, several prospective studies have suggested an increased risk of psychosis among cannabis users, with alternative explanations failing to account for such an effect. A cause–effect relationship has thus been implied. Further evidence has indicated that there is a dose–response relationship, and high-potency cannabis varieties confer the greatest risk of psychosis. As cannabis use has become more common over the last decades, one would expect a related increase in the number of schizophrenia cases. However, evidence in this regard remains equivocal for several reasons, including relying on databases that are not primarily designed to address such question and the issue that solid information regarding the incidence of schizophrenia is a relatively recent acquisition. Recent years have seen the development of online web publications, such as Google Trends and “Our World in Data”, where data are explorable and interactable for tracking and comparing trends over specific periods and world regions. By using such databases, we believe that the question whether changes in cannabis use are associated with changes in schizophrenia rates can be answered, at least partly. Therefore, we tested these tools by evaluating trends in cannabis use and both cases and prevalence of schizophrenia in the United Kingdom, one of the countries where the incident rates for psychotic disorder have been suggested to be particularly increased by cannabis consumption. Crossing data from these tools revealed that interest in cannabis has been growing at the country level for over 10 years, with a parallel overlapping raise in psychosis cases and prevalence. Following up on this example, let us think of how many public health opportunities these public resources may offer. The question now is whether public health interventions for the benefit of the general population will follow suit.
Citations in the library
Cites 6
- Is there sufficient evidence that cannabis use is a risk factor for psychosis? 2020
- The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study The Lancet Psychiatry May 1, 2019
- Cannabis and psychosis: what do we know and what should we do? The British Journal of Psychiatry April 1, 2018
- Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition Current Addiction Reports April 29, 2017
- Cannabis in Chinese Medicine: Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids? Frontiers in Pharmacology March 10, 2017
and 1 more in the library